Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07258407 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
A Phase 1 study of Metastatic Castration-Resistant Prostatic Cancer, sponsored by T.O.A.D. Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 4
- Study locations
NCT07258407 is a Phase 1 study of Metastatic Castration-Resistant Prostatic Cancer that is actively recruiting participants, run by T.O.A.D. Oncology. The registered enrollment target is 180 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT07258407, a Phase 1 study of Metastatic Castration-Resistant Prostatic Cancer, is actively recruiting participants, sponsored by T.O.A.D. Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
Conditions Studied
Interventions
- DRUG TD001
Study Locations (4)
Other
- Institut Bergonié - Bordeaux
- Hôpital Paris Saint Joseph - Paris
- Institut Gustave Roussy - Villejuif
Connecticut
- Yale University, Yale Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07258407
The ClinicalTrials.gov registry entry for NCT07258407 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is T.O.A.D. Oncology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-Resistant Prostatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which TD001 is the first listed.
NCT07258407 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07258407 about?
NCT07258407 is a clinical study titled "A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer". This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
What is the current status of trial NCT07258407?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-01-30. Estimated completion is 2029-03.
What conditions does trial NCT07258407 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostatic Cancer.
What interventions are being tested in trial NCT07258407?
The interventions under investigation include: TD001 (DRUG).
Who is sponsoring clinical trial NCT07258407?
This trial is sponsored by T.O.A.D. Oncology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07258407 being conducted?
This trial has 4 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.